TNB-486 (also known as AZD0486) "is a novel CD19xCD3 bispecific T-cell engager (TCE) that incorporates a unique anti-CD3 moiety designed to reduce cytokine release…
TNB-486 (also known as AZD0486) "is a novel CD19xCD3 bispecific T-cell engager (TCE) that incorporates a unique anti-CD3 moiety designed to reduce cytokine release syndrome by binding to T-cells with low affinity". The drug is developed for cancer by AstraZeneca since its acquisition of TeneoTwo in 2022.
References
Gebaseerd op: Wikipedia — TNB-486 · auteursgeschiedenis.
Tekst: CC BY-SA 4.0.
Wikisyntaxis en sjablonen zijn verwijderd; langere teksten zijn ingekort.